118 related articles for article (PubMed ID: 12712441)
1. Genetic analysis of benign ovarian tumors.
Thomas NA; Neville PJ; Baxter SW; Campbell IG
Int J Cancer; 2003 Jul; 105(4):499-505. PubMed ID: 12712441
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis.
Watson RH; Neville PJ; Roy WJ; Hitchcock A; Campbell IG
Oncogene; 1998 Jul; 17(2):207-12. PubMed ID: 9674705
[TBL] [Abstract][Full Text] [Related]
3. Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours.
Roy WJ; Watson RH; Hitchcock A; Campbell IG
Oncogene; 1997 Oct; 15(17):2031-5. PubMed ID: 9366520
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of peritoneal fluid in ovarian cancer patients.
Parrella P; Zangen R; Sidransky D; Nicol T
Mod Pathol; 2003 Jul; 16(7):636-40. PubMed ID: 12861058
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas.
Plisiecka-Hałasa J; Dansonka-Mieszkowska A; Kraszewska E; Dańska-Bidzińska A; Kupryjańczyk J
Anticancer Res; 2008; 28(2A):989-96. PubMed ID: 18507046
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.
Gras E; Cortes J; Diez O; Alonso C; Matias-Guiu X; Baiget M; Prat J
Cancer; 2001 Aug; 92(4):787-95. PubMed ID: 11550149
[TBL] [Abstract][Full Text] [Related]
9. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis.
Xu B; Hamada S; Kusuki I; Itoh R; Kitawaki J
Gynecol Oncol; 2011 Feb; 120(2):239-46. PubMed ID: 21130491
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women.
Szych C; Staebler A; Connolly DC; Wu R; Cho KR; Ronnett BM
Am J Pathol; 1999 Jun; 154(6):1849-55. PubMed ID: 10362811
[TBL] [Abstract][Full Text] [Related]
11. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic changes associated with ovarian cancer.
Weitzel JN; Patel J; Smith DM; Goodman A; Safaii H; Ball HG
Gynecol Oncol; 1994 Nov; 55(2):245-52. PubMed ID: 7959292
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci.
Jiang X; Hitchcock A; Bryan EJ; Watson RH; Englefield P; Thomas EJ; Campbell IG
Cancer Res; 1996 Aug; 56(15):3534-9. PubMed ID: 8758923
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity at 7q22 and mutation analysis of the CDP gene in human epithelial ovarian tumors.
Neville PJ; Thomas N; Campbell IG
Int J Cancer; 2001 Feb; 91(3):345-9. PubMed ID: 11169958
[TBL] [Abstract][Full Text] [Related]
15. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types.
Okada S; Tsuda H; Takarabe T; Yoshikawa H; Taketani Y; Hirohashi S
Jpn J Cancer Res; 2002 Jul; 93(7):798-806. PubMed ID: 12149146
[TBL] [Abstract][Full Text] [Related]
16. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
[TBL] [Abstract][Full Text] [Related]
17. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
Kolasa IK; Rembiszewska A; Janiec-Jankowska A; Dansonka-Mieszkowska A; Lewandowska AM; Konopka B; Kupryjańczyk J
Gynecol Oncol; 2006 Nov; 103(2):692-7. PubMed ID: 16793127
[TBL] [Abstract][Full Text] [Related]
18. Absence of PPP2R1B gene alterations in primary ovarian cancers.
Campbell IG; Manolitsas T
Oncogene; 1999 Nov; 18(46):6367-9. PubMed ID: 10597236
[TBL] [Abstract][Full Text] [Related]
19. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas.
Suzuki M; Saito S; Saga Y; Ohwada M; Sato I
Cancer Genet Cytogenet; 2000 Apr; 118(2):132-5. PubMed ID: 10748293
[TBL] [Abstract][Full Text] [Related]
20. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity.
Zborovskaya I; Gasparian A; Karseladze A; Elcheva I; Trofimova E; Driouch K; Trassard M; Tatosyan A; Lidereau R
Int J Cancer; 1999 Sep; 82(6):822-6. PubMed ID: 10446448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
